Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Aichi Medical University is currently navigating 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The data shows that prosecution activity is limited to 1 distinct examiner and 1 distinct art unit. This indicates a narrow focus for the university's current patent filings with all active matters localized in one technical area.
The busiest examiner identified is TCHERKASSKAYA, OLGA V, who is assigned 1 busiest examiner pending office action. Since the portfolio only contains 1 distinct examiner, TCHERKASSKAYA, OLGA V is managing the full extent of the university's pending actions. This creates a direct link between the examiner's specific standards and the university's overall prosecution success.
The 1 distinct art unit involved suggests that the technical review is confined to a single specialized group. The 1 pending office action represents the total current administrative burden for the university's portfolio. This focused profile suggests that the university is managing a specific set of claims under the oversight of 1 distinct examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TCHERKASSKAYA, OLGA V | 1 | 55.5% | +46.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17795521 | VASODILATOR COMPOSITION, VASODILATOR COMPOSITION KIT, PHARMACEUTICAL COMPOSITION FOR DISEASE CAUSED BY VASCULAR STENOSIS OR VASCULAR OCCLUSIVE DISORDER, AND PHARMACEUTICAL COMPOSITION KIT FOR DISEASE CAUSED BY VASCULAR STENOSIS OR VASCULAR OCCLUSIVE DISORDER | TCHERKASSKAYA, OLGA V | 14d |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17795521 | VASODILATOR COMPOSITION, VASODILATOR COMPOSITION KIT, PHARMACEUTICAL COMPOSITION FOR DISEASE CAUSED BY VASCULAR STENOSIS OR VASCULAR OCCLUSIVE DISORDER, AND PHARMACEUTICAL COMPOSITION KIT FOR DISEASE CAUSED BY VASCULAR STENOSIS OR VASCULAR OCCLUSIVE DISORDER | TCHERKASSKAYA, OLGA V | 1615 | §112 | Final Rejection | 14d | Pending | Jul 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAichi Medical University has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Olga V Tcherkasskaya has the most, with 1 of Aichi Medical University's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
